Ikena Oncology, Inc. (IKNA)
- Previous Close
1.3200 - Open
1.3500 - Bid 1.3100 x 200
- Ask 1.3600 x 100
- Day's Range
1.3100 - 1.3500 - 52 Week Range
1.0200 - 7.3800 - Volume
90,214 - Avg. Volume
397,681 - Market Cap (intraday)
64.183M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6300 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
ikenaoncology.comRecent News: IKNA
Performance Overview: IKNA
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IKNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IKNA
Valuation Measures
Market Cap
63.70M
Enterprise Value
-101.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.01
Price/Book (mrq)
0.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.04%
Return on Equity (ttm)
-48.28%
Revenue (ttm)
3.85M
Net Income Avi to Common (ttm)
-70.09M
Diluted EPS (ttm)
-1.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
157.35M
Total Debt/Equity (mrq)
6.27%
Levered Free Cash Flow (ttm)
-44.59M
Research Analysis: IKNA
Company Insights: IKNA
IKNA does not have Company Insights